New combo therapy aims to stop head and neck cancer return
NCT ID NCT00875849
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested whether adding the targeted drug cetuximab to standard chemotherapy and radiation could help prevent head and neck cancer from coming back after surgery. The study enrolled 53 patients with certain high-risk features. The main goal was to see how many patients remained cancer-free after two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cetuximab (a targeted antibody), cisplatin (chemotherapy), and radiation therapy
What this could lead to
If successful, this combination could improve the chance of keeping head and neck cancer from returning after surgery.
What could go wrong
This is a small, early-phase trial with only 53 participants. The added drugs may cause more side effects, and it's unclear if the benefits outweigh the risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France